If value-based pharmaceutical pricing were in place, drug makers would get paid based on the benefits their products provide to patients and society, rather than simply on their production costs. As this new payment model starts to gain traction, Commonwealth Fund President David Blumenthal, M.D., asks in To the Point how much a currently inexpensive drug like penicillin would cost under this system. He calls for a cautious approach.
